A better understanding of the interactions between endothelial dysfunction and the NLRP3 inflammasome-regulated pathways may open up a new avenue for effective treatment of cardiovascular complications in metabolic diseases including T2DM. This evidence concerns the gene NLRP3 and metabolic disease.